Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: A comparative study

International Journal of Gynecological Cancer

Volumn 21, Issue 4, 2011, Pages 661-667

  Greggi, Stefano ^a   Mangili, Giorgia ^b   Scaffa, Cono ^a   Scala, Felice ^a   Losito, Simona ^c   Iodice, Francesco ^a   Pisano, Carmela ^c   Montoli, Serena ^a   Viganò, Riccardo ^a   Pirozzi, Giuseppe ^a   Giannarelli, Diana ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Hospitale San Raffaele   (Italy)

^c Surgical Pathology ^*  (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Clear cell; Endometrioid carcinoma; Uterine papillary serous

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLEAR CELL CARCINOMA; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; PAPILLARY CARCINOMA; PERITONEUM METASTASIS; PLOIDY; POORLY DIFFERENTIATED ENDOMETRIOID CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; UTERINE PAPILLARY SEROUS CARCINOMA; UTERUS;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CELL DIFFERENTIATION; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 80051890062     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182150c89     Document Type: Article

References (27)

1. Bray F, Loos AH, Oostindier M, et al. Geographical and temporal variations in cancer of the corpus uteri: incidence and mortality in pre and post-menopausal women in Europe. Int J Cancer. 2005;117:123-131. (Pubitemid 41262766)
2. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri: FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet. 2006;95:S105-S143.
3. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004;11:117-142.
4. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54:264-268. (Pubitemid 24301898)
5. Abeler VM, Vergote IB, Kjorstad KE, et al. Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern. Cancer. 1996;78:1740-1747. (Pubitemid 26330902)
6. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage IYII endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002;54:79-85.
7. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95: 593-596. (Pubitemid 39610410)
8. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642-646. (Pubitemid 43361894)
9. Boruta DM 2nd, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer. 2004;101:2214-2221. Comment in: Cancer 2004;101:2152-4. (Pubitemid 39458676)
10. Halperin R, Zehavi S, Langer R, et al. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study. Eur J Gynaecol Oncol. 2002;23: 300-304. (Pubitemid 34948044)
11. Poulsen H, Taylor CW, Sobin LH. Histologic typing of female genital tract tumors. In: International Histologic Classification of Tumors. No 13. Geneva, Switzerland: World Health Organization; 1975.
12. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982; 6: 93-108. (Pubitemid 12108965)
13. Abeler UA, Kjorstad KE. Endometrial adenocarcinoma with squamous cell differentiation. Cancer. 1992;69: 488-492.
14. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine papillary serous carcinoma, a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16:600-610.
15. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47:298-303
16. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009;105:103-104.
17. Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115: 244-248.
18. Wright JD, Fiorelli J, Schiff PB, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer. 2009;115:1276-1285.
19. Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192: 813-818. (Pubitemid 40311274)
20. Cirisano FD, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77:55-65. (Pubitemid 30217305)
21. Goldberg H, Miller RC, Abdah-Bortnyak R, et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol. 2008;108:298-305.
22. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control. 2009;16:46-52.
23. Slomovitz BM, Broaddus RR, Burke TW. Her2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22:2136.
24. Mangili G, Montoli S, De Marzi P, et al. The role of DNA ploidy in postoperative management of stage I endometrial cancer. Ann Oncol. 2008;19:1278-1283. (Pubitemid 351911957)
25. Susini T, Amunni G, Molino C, et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma. Cancer. 2007;109:882-890.
26. Baak JP, Snijders W, van Diermen B, et al. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in International Federation of Gynecology and Obstetrics stage 1 and 2 endometrial carcinoma. J Clin Oncol. 2003;21:4214-4221. (Pubitemid 46606191)
27. Kato DT, Ferry JA, Goodman A, et al. Uterine papillary serous carcinoma: a clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59:384-389.